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1.  Study Protocol 
 
Aims Of The Project 
Aim 1:  To test whether community-based periodic treatment of children 6-23 months old with 
mebendazole will decrease rates of severe anemia and protein-energy malnutrition by at least 20%. 
Aim 2:  To determine whether young children infected with intestinal nematode infections exhibit a 
more pro-inflammatory response to nematode antigens (i.e. characteristic of T Helper 1 [Th1] cells) 
than age-matched uninfected children. 
Aim 3:  To test whether mebendazole treatment of infected children reverses this pro-inflammatory 
response. 
Aim 4:  To measure intestinal blood loss related to relatively light hookworm infection in young 
children, and whether intestinal blood loss is reduced after treatment with mebendazole.   
Aim 5:  To elucidate metabolic mechanisms that could explain the link between a pro-inflammatory 
cytokine response and anemia and protein-energy malnutrition.  Specifically, we aim: 
A) To determine whether newly infected children show defects in iron metabolism compared to 
age-matched uninfected children, in a manner consistent with mechanisms of the “anemia of 
chronic disease” (i.e. decreased iron absorption, decreased iron incorporation into erythrocytes, 
suppressed erythropoiesis, and/or shortened red cell life span); 
B) To determine whether newly infected children catabolize protein at greater rates than age-
matched uninfected children; 
C) To determine whether newly infected children are more anorexic than age-matched 
uninfected children. 
 
Background And Preliminary Data 
 Malnutrition, measured as low weight-for-age, is one of the strongest known risk factors for 
child mortality in developing countries.  Based on an analysis of data sets from several diverse 
geographic and socio-cultural locations, 25 and 50% of child deaths between the ages of 1 and 4 
years were statistically attributable to malnutrition 1.  Although the risks associated with severe 
malnutrition are highest, more deaths are attributable to mild-moderate malnutrition, because it is 
so common. The relative contribution of mild-moderate malnutrition is especially great in sub-
Saharan Africa1.  Severe anemia may also contribute to mortality in children, especially when it 
coexists with respiratory illness2;3.  Both protein-energy malnutrition and anemia are also 
associated with behavioral alterations and delays in child development4-6. 
 The causes of childhood malnutrition are multiple.  Inadequate dietary intakes of calories 
and essential nutrients are a major cause7, but infectious diseases contribute significantly to both 
anemia and poor growth 8.   The role of subclinical infection as a cause of poor growth in young 
children was hypothesized long ago 9, but its importance in populations has been difficult to 
demonstrate10.   The hypothesized pathways are mediated by pro-inflammatory cytokines that 
suppress appetite11;12, cause losses of protein13;14, and raise resting energy expenditure15.  These 
processes have been best described in adults with chronic disease, but may be particularly 
important in young children in developing countries.   
The role of subclinical infection or inflammation as a cause of anemia—the so-called 
anemia of chronic disease16—is much better described.  This too is mediated by cytokines, which 
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have been shown to inhibit erythropoietin secretion17;18 and block its action on the bone marrow19-
21.  Iron deficiency is generally considered the predominant cause of anemia in children in 
developing countries22, but the role of subclinical infection as a cause of anemia may be grossly 
underestimated.   
The research we propose to carry out in rural Tanzania is designed to test the hypothesis 
that intestinal nematode infections in young children contribute significantly to protein-energy 
malnutrition and anemia through a cytokine-mediated inflammatory response.  Geo-helminth 
infections may be the most common subclinical infection encountered by children in tropical 
environments. The global prevalence of helminth infections is very high—with 20-30% of the 
world’s children affected23.  In Zanzibar infection with at least one of the intestinal nematodes 
(hookworm, Trichuris trichiura, or Ascaris lumbricoides) is nearly universal by the age of 3 years. 
The public health motivation for studying these infections is strong, as drugs for treatment are 
inexpensive and widely available.  The biomedical motivation is also compelling, as they can be 
safely studied through randomized trials.  Thus, we believe this research will provide practical 
guidance to public health programs and will test a novel model for elucidating the role of 
subclinical infection and inflammation as a cause of malnutrition and anemia in early childhood.   
 
Figure 1.  Conceptual Framework 
Randomized 
Intervention  Mediating variables 
Outcome 
variables 
 Intestinal bleeding Iron metabolism 
Mebendazole 
Acute phase proteins Erythropoiesis 
Anemia 
Helminth 
Infection Proinflammatory cytokines Protein catabolism 
Placebo 
 Humoral immune response Anorexia 
Protein-energy 
malnutrition 
 
The hypothesis that subclinical intestinal nematode infections may cause wasting 
malnutrition and the “anemia of chronic disease” in young children is supported by preliminary 
data from a randomized trial we recently completed in rural Zanzibar (Table 1).  A community-
based sample of 614 children 6-71 months of age was individually randomized to receive 3-
monthly mebendazole (500 mg) or an identical placebo.  Our aim was to define the preschool age 
range in which anthelminthic treatment may be beneficial to child growth and development, and 
our prior hypothesis was that mebendazole would improve growth and hemoglobin in preschoolers 
≥ 3 years old.  Contrary to our expectation, we found significant benefits from anthelminthic 
treatment in children <30 months of age, in whom infection intensities were light but in whom 
incident infections were common.  In this younger age group, mebendazole-treated children 
showed no improvement in iron status, and their levels of serum ferritin (both an iron storage 
protein and an acute phase protein) decreased by a large amount.  Clinical morbidity symptoms 
were carefully monitored, and no deleterious effects of mebendazole treatment were observed in 
any age group.  P. falciparum is holo-endemic in Zanzibar and clinical cases were treated when 
detected, but no malaria prevention program was implemented during the study period. The 
reductions in wasting malnutrition and moderate-severe anemia were large compared to other 
feasible public health interventions, and may be associated with improvements in child survival and 
development.  However, the statistical significance of the changes was marginal, and the study 
needs to be repeated in a larger sample of children.  
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Table 1.  Effects of regular mebendazole treatment on rates of low hemoglobin and wasting 
malnutrition in Pemban children 6-29 months old 
 Mebendazole group 
(n=85) 
Placebo group 
(n=99) 
Relative Risk 
(95% confidence limits) 
 Prevalence rates (%)  
Hemoglobin < 90 g/L 24.7 36.8 0.68 (0.43-1.07) 
WHZ < -1 22.7 34.8 0.65 (0.40-1.05) 
MUAC < 13.5 cm 12.0 22.0 0.53 (0.27-1.05) 
Poor appetite 4.7 12.1 0.42 (0.14-1.28) 
Stoltzfus RJ, Chwaya HM, Montresor A, Albonico M, Tielsch JM, Savioli L, unpublished data.  Children were individually randomized to receive 
mebendazole (500 mg) or placebo every 3 months for a 12-month period.  WHZ=weight-for-height Z score, result is adjusted for baseline value.  
MUAC=mic-upper-arm circumference, result is adjusted for baseline value and age. 
 
This surprising benefit to young children might be explained by one or both of two things:  
(1) Children in this age period are at highest risk for the outcomes of severe anemia and wasting 
malnutrition (well documented facts consistent with our own data) and so are most vulnerable to 
the deleterious effects of worms, and/or (2) Children during the same period are acquiring first-time 
helminth infections with acute inflammatory sequelae that are especially detrimental to nutrient 
metabolism, appetite, and erythropoiesis.   
This “incident inflammatory response” might involve:  Th1 subset activation and interferon-
γ (IFN-γ) production; IFN-γ activation of macrophages to produce such proinflammatory 
monokines as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α); 
monokine induction of proinflammatory mediators and acute phase proteins.  This novel hypothesis 
is consistent with the reduction in serum ferritin that we observed when young Pemban children 
with light infections were treated with mebendazole.     
Although chronic gastrointestinal (GI) infections typically stimulate marked Th2 responses 
characterized by IgE and eosinophilia24, nothing is known of the characteristics and subsequent 
development of the acute primary responses in the very young.  Studies in rodent models of GI 
nematode infections have shown that the nature of the cytokine response (Th1 or Th2) to a primary 
infection is influenced by the host genetic background25 and also by the dose of infective stages26.  
In this latter study, in the Trichuris muris mouse model, a high infective dose of eggs stimulated a 
strongly Th2-polarized response whereas a light infection stimulated a strong Th1 response (>12-
fold increase in IFN-γ).  Repeated trickle infection in this murine model eventually led to an 
increased Th2 response27.  A switch from Th1 response on primary exposure to a Th2 response 
following repeated infection has also been shown with Schistosoma mansoni infections in baboons.  
Initial GI nematode infections in young humans will invariably be light and so it seems plausible 
that infants will make a significant proinflammatory response on first exposure and that this may 
modulate to a Th2 response with repeated exposure in the absence of treatment.  Similar to the 
differences observed between different mouse strains, human populations also show a marked 
variation in predisposition to worm infections and host genetic effects on the immune response may 
similarly influence this28.  Thus the tendency to produce proinflammatory responses may vary 
markedly within the population.   
Thus, a major focus of this study will be to assess, for the first time, the balance of worm-
induced Th1- and Th2-associated cytokines in newly infected infants and how this is influenced by 
treatment.  There is also emerging evidence that helminth (filarial) infections in mothers sensitize 
for parasite-specific immune responsiveness in neonates29;30 and that this involves both Th1 and 
Th2 cytokines, with the pro-inflammatory cytokine IFN-γ prominent31.  On first exposure to 
infection, therefore, marked secondary responses may be induced.  Whether GI nematode infections 
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have similar effects is unknown but in Pemba infection rates in women of child-bearing age are 
very high.  In 1995 we conducted a community-based survey of 582 Pemban women of 
reproductive age, and found that 91% were infected with hookworms32.  For this reason we will 
assess maternal helminth infection rates as a potential covariate of infant immune response to 
infection. 
 
Experimental Design and Methods 
 We propose to conduct a community-based individually randomized trial of 3-monthly 
mebendazole treatment to assess the outcomes described in the framework and aims.  The study 
area will be a geographically contiguous group of villages selected for the convenience of sample 
transport to the laboratory (within about 30 minutes drive by landrover).  The PHL is currently 
conducting a complete population census of Pemba Island, which will allow us to define an area 
large enough to generate the needed sample size.   
A representative sample of 2500 children ages 6-23 months will be screened for helminth 
infection.  All 2500 children will be randomly allocated to treatment with a 3-day course of 
mebendazole, 100 mg twice daily, or identical placebo.  This regimen was chosen to replicate the 
same drug used in our preliminary trial, but to maximize the efficacy of this drug against 
hookworms and T. trichiura.  The study period will be 12 months duration, so that children have 
their first and final assessments in the same calendar month of the year, thus holding constant any 
seasonal effects.  Anemia and PEM (Aim 1) will be assessed in the full sample. 
To answer Aims 2 & 3, age-matched triplets of children will be selected according to their 
infection status at baseline.  A triplet will be comprised of two infected and one uninfected child of 
similar age.  The two infected children will be matched for species of infection.  250 matched 
triplets (total n=750) will comprise the Immunology Subsample.  We chose 2:1 matching of 
infected to uninfected, because we are dealing with 3 species of infection and we want to increase 
our capacity to examine differences by species.  Based on our preliminary data, a starting sample of 
2500 children will be required to generate at least 500 infected cases.  These children will be 
assessed for immunological parameters at baseline (prior to treatment) and again in the 10th month 
of the study, one month after the 4th (9-month) treatment round.  The post-treatment time was 
chosen to maximize treatment effect by capturing all 4 rounds of treatment and by timing the 
assessment one month after the final treatment, when egg counts should be maximally reduced by 
the mebendazole. 
To answer Aim 4, a subsample of 300 children will be constructed of hookworm-negative 
(n=100), light hookworm infections (1-999 epg, n=100) and moderate hookworm infections (≥1000 
epg, n=100). These classifications are lower than typically used in school children, and were 
chosen for children 6-24 month who have lighter infection intensities but whose total body iron 
store is limited or absent.  Therefore small quantities of GI blood loss could have significantly alter 
their iron balance.  Intestinal blood loss will be measured in this subsample at just prior to 
treatment, and 1 and 12 months post-treatment.  This HemoQuant subsample will be drawn from 
the Immunology Subsample, so that immunologic data will also be available.   
To answer Aims 5A and 5B, a subsample of 20 newly-infected and 20 uninfected (total 
n=40) children will be selected from the Immunology Subsample.  This number, although small for 
an epidemiologic study, is large for a metabolic study involving stable isotopes.  To our knowledge 
it is the largest sample size ever involved in a similar protocol.  However, many factors may affect 
the metabolism of these children and it is essential to limit the heterogeneity within this sample to 
reduce variance unrelated to the factors of interest (i.e. helminth infection status and cytokine 
response).  Thus, we will impose inclusion criteria based on age (12-23 months old), wasting 
malnutrition (weight-for-height Z scores ≥-1), recent illness (no significant morbidity in the prior 2 
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weeks, and malaria infection (<1000 parasites/mL).  Because these children will be drawn from the 
age-matched triplets defined for the Immunology study, the 20 children in the newly-infected group 
and the uninfected groups will be further matched on age within the 1-year-old age category.  
Specific Aim 5C will be addressed using maternal reports of poor appetite, a method that is valid33 
and very simple to implement.  Therefore anorexia will be assessed in the full sample of 2500 
children just prior to treatment and at 3, 6 and 12 months post-treatment.   
 
Figure 2.  Data collection schedule. 
Study Month: 0 1 2 3 4 5 6 7 8 9 10 11 12 
FULL SAMPLE (n = 2500) 
Fecal samples X            X 
Randomized Rx X   X   X   X   X 
Capillary blood1 X   X   X   X   X 
Appetite X   X   X   X   X 
MUAC X   X   X   X   X 
Mother’s milk2 X             
IMMUNOLOGY SUBSAMPLE (n=750) 3 
Mother’s fecal X          X   
Venous blood4 X          X   
Anthropometry X          X   
HemoQuant5 X          X   
1) Capillary blood sample for determination of hemoglobin and malaria parasite density.  
2) Only collected from mothers of children 6-12 months old.  
3) Data collected in subsamples are in addition to the data collected for the full sample. 
4) Venous blood sample will be used for assays of cytokine secretion in response to 
antigenic stimulation (whole blood asay), acute phase proteins, immunoglobulins,  and 
iron status indicators.   
5) HemoQuant assay will be performed on fecal samples collected for parasitology; no 
additional samples will be collected.   
 
 
Justification Of Sample Size 
 Our starting point for the sample size calculation was the Immunology Subsample.  The 
proposed starting sample size of about 750 children, after 15% attrition, provides 220 children per 
infection status group, randomly allocated into 2 treatment groups.  Thus to compare treatment 
effects within infection groups, we plan to have about 110 children.  Based on the ongoing work of 
Drs. Taylor, Bickle, and Weir in Nanjing China, where they are using the whole blood assay to 
assess cytokine reponses to Schistosoma mansoni, 100 per group is a minimum number to detect 
important differences. 
 To generate this number of age-matched triplets for the Immunology Subsample, about 
2500 children will need to be screened for infection.  This will in fact be more than enough to 
address Aim 1.  However, we propose to retain the entire group of 2500 children for several 
reasons.  First, we want to retain the representative community-based sample to address Aim 1.  
The Immunology Subsample will be specifically constructed such that it is no longer representative 
of the community of young children.  We want to make inference about the effects that would be 
observed if mebendazole treatment were provided to all young children in this environment, since 
screening for infection status would be impossible to implement in a public health program.  
Second, it has been our experience in Pemba that once community meetings have been held to 
inform and motivate participation in a research study, it is difficult to randomly select only some of 
the children into the actual study.  Because participation in the study will confer some benefits to 
the study subjects and their communities, families resent being excluded from community-based 
studies.  Third, the costs of implementing the Full Sample protocol are relatively small. 
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 The sample size for the HemoQuant Subsample, 100 per infection intensity group, was 
based on our previous HemoQuant study of hookworm-related blood loss in Pemba school 
children34.  In that study we detected significant differences amongst infection intensity groups with 
50 children per group, however, the spectrum of infection intensities in school children was much 
greater.  Because infection intensities will be light in these young children, we have doubled our 
previous sample size to detect smaller blood losses. 
 The sample size for the metabolic studies was based on the high cost of isotopes and their 
analysis, and our previous experience conducting studies of this sort.  Groups of 10 individuals are 
typical of most metabolic studies that use stable isotopes.  The proposed sample size of 40 children 
will be large in the published literature; however, the heterogeneity of the children (with regard to 
nutritional status, malaria, and other recent infections) will be greater than most populations that 
have been studied. 
 
Assessment Methods For Full Sample 
Helminth infection will be assessed by fecal egg counts determined by quantitative formalin ether 
concentration technique. Presence and intensity of GI nematode infections will be assessed by the 
Formol ether method on a weighed amount of mixed feces (≈1 g). The eggs present in the whole 
sediment will be counted in McMaster chambers except if very high numbers of a particular species 
is present, in which case a known proportion of the graduated slide will be counted.  
Anemia will be assessed by hemoglobin concentration using the HemoCue method35.  When 
capillary blood samples are assessed (full sample protocol), the third drop of blood will be used36.  
Severe anemia will be defined as hemoglobin <7 g/dL. 
Malaria parasite density will be determined by counting parasites against leukocytes in a thick 
blood film, according to standard methods37. 
Anorexia will be assessed by maternal recall using established techniques38;39.  
PEM will be assessed by weight, length, and arm circumference-for-age40 following standard 
protocols.41  
 
Additional Assessment Methods For Immunology Subsample 
Phlebotomy.  Blood (5 mL sample) will be drawn at comparable times of the day into a vacutainer 
without anti-coagulant.  1 ml will be immediately dispensed into a sterile tube with heparin to be 
used in the whole blood assay (below).  Additional drops will be used to make blood films for total 
leukocyte and reticulocyte counts, and malariometry.  The remaining 2 ml will be allowed to clot 
and serum will be collected.   
Whole Blood Assay to evaluate T cell responses.  This assay will be carried out as described 
previously42. Cells will be stimulated with worm antigens (Trichuris, hookworm or Ascaris); the 
mitogen, PHA; and purified protein derivative (PPD) of Mycobacterium tuberculosis. PPD has 
been chosen as a positive control antigen as BCG vaccination is given at birth. Supernatants will be 
harvested at appropriate times for measurement of Interleukin (IL-) 4, 5, 6, 10, 13, TNF-α  and 
IFN-γ.  Optimum harvesting time for each cytokine to the antigens will be defined in the study 
population in project year 1.  Cytokines will be measured by quantitative ELISA using 
commercially available antibody pairs and recombinant cytokine standards (Pharmingen). To 
control for interplate variation, a positive control supernatant from bulk PHA or LPS stimulated 
cultures will be used on all plates. IL-4, IL-13, and IL-5 have been chosen as indicators of 
activation of Th2 type responses, each of which also plays a defined role in the protective immune 
response against helminth infections43. IL-10 is implicated in the suppression of IFN-γ mediated 
Th1 responses, for example in the early response to S. mansoni infection in humans44.  IFN-γ has 
been chosen as a measure of Th1 activation, and for its important role in the induction of TNF-α. 
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TNF-α and IL-6 are proinflammatory cytokines (which induce acute phase proteins) produced by 
macrophages following their activation by IFN-γ.  TNF-α may play a direct role in regulating Th2 
responses to helminths45, and has a direct effect on cachexia and wasting.  All of these cytokines 
have been measured in whole blood cultures using the techniques developed by Weir et al. (1999 
and unpublished) and by others46.  The utility of measuring cytokine responses in the peripheral 
blood as an indicator of responses elsewhere in the body has recently been confirmed47.  Antigens 
for the whole blood assay will be prepared as follows.  Trichuris, hookworm and Ascaris adult 
worms will be recovered by Quantrel (pyrantel/oxantel) treatment of children and adults in the 
areas in which the main study will be carried out. Worms will be frozen at –70oC and antigen 
prepared in culture medium by sonication and centrifugation. Protein will be estimated and the 
antigen concentration optimized for use in the WBA and specific antibody ELISAs. 
Serum acute phase proteins. Inflammation will be assessed by ELISA assay of serum C-reactive 
protein (CRP), α-1-anti-trypsin (α-1-AT), ferritin and eosinophil cationic protein (ECP) in venous 
samples.  CRP and α-1-AT are acute phase proteins known to suppress erythropoiesis19;21, ferritin 
is both an iron storage protein and a positive acute phase protein, and ECP is a marker of eosinophil 
activity that is elevated in helminth infections48;49.  CRP and α-1-AT will be assessed by in-house 
ELISA assay systems based on enzyme-labelled (CRP) and biotinylated (α-1-AT) purified 
proteins50.   Ferritin will be measured using the commercial kit made by Ramco, Inc.  We will 
develop an ELISA system for assaying ECP following Reimert et al51.   
Antibody detection.  Total IgE, a marker of established infections with many species of helminth, 
will be measured using the Pharmacia ImmunoCap method 52. Isotype-specific antibody responses 
will be assessed by ELISA for IgG, IgG1 (associated with Th1 responses), IgG4 and IgE (both 
associated with Th2 responses) against hookworm, Ascaris, and Trichuris antigens. The 
contribution of maternal-derived antibody to that measured in the children’s sera may be uncertain 
but the data will be valuable in conjunction with information on infection presence and intensity.  
Iron status will be assessed by measurement of erythrocyte protoporphyrin in a drop of whole blood 
using a digital hematofluorometer (Aviv Biomedical).  Serum ferritin and transferrin receptor will 
also be measured and will be considered as iron status indicators.  However, our prior experience in 
young Pemban children53 suggests that serum ferritin mainly reflects the acute phase response, and 
that transferrin receptor mainly reflects erythropoiesis in this population.  In contrast, erythrocyte 
protoporphyrin was relatively specific to iron deficiency.  
Erythropoiesis will be assessed according to the model of Beguin54, which evaluates erythropoietin 
concentration, transferrin receptor concentrations and reticulocyte index relative to hemoglobin 
concentration.  Erythropoietin and transferrin receptor concentrations will be measured using 
commercial ELISA kits.  Reticulocyte counts will be made on thin blood films examined 
microscopically. 
Morbidity  in the week prior to each immunology assessment will be assessed by maternal recall 
using local terms for acute symptoms. 
  
Additional Assessment Methods For HemoQuant Subsample 
Intestinal bleeding will be assessed by the HemoQuant assay55;56.  This assay measures the quantity 
of heme excreted per gram of feces.  In subjects who consume little red meat intake (like young 
Pemban children), this is an accurate measure of intestinal blood loss. 
 
Additional Assessment Methods For Metabolic Subsample 
The sequence of the metabolic studies is shown in Table 3.  Protein catabolism, iron absorption and 
iron incorporation into red cells will be assessed before mebendazole treatment.  Pre-treatment 
measures in newly infected and uninfected children will allow us to test cross-sectionally for 
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metabolic changes associated with new infections.  We will also assess body composition and 
plasma volume.  This is necessary to estimate body pool sizes, which may differ from normal 
assumptions because of the chronic mild malnutrition and subclinical infections in Pemban 
children.  One month post-treatment we will reassess protein catabolism, and assess red cell 
survival rates.  Post-treatment values will allow us to assess whether mebendazole reduces protein 
catabolism or alters red cell life span.  
 
Figure 3.  Summary of metabolic studies 
 Time relative to mebendazole treatment 
 2 weeks pre-treatment On day of treatment 1 month post-treatment 
Iron metabolism Administration of iron 
isotopes 
Assessment of iron absorption 
and incorporation into red cells 
Assessment of red cell 
survival 
Protein catabolism Pre-treatment protein turnover 
study  
 Post-treatment protein 
turnover study 
Body composition 
and plasma volume 
Isotopic dilution; Sodium 
bromide dilution 
  
 
General procedures. Infants will be brought to an outpatient clinical facility at the Pemba PHL 
accompanied by an adult relative.  The atmosphere will be designed to provide comfort and 
entertainment for the infants, mothers and any siblings who come along.  A medical doctor will be 
present throughout every protocol, which will be implemented by experienced pediatric nurses.  
Appropriate incentives will be given to families who participate to compensate their time and 
inconvenience. 
Iron metabolism protocol. Iron absorption and red cell iron incorporation will be measured by 
administering oral (57Fe) and intravenous (58Fe) stable iron isotopes to each infant.  Blood samples 
will be taken 2 weeks post-dosing to measure the enrichment of these tracers in red blood cells.  
The enrichment of isotopes in this sample will allow us to measure both iron absorption and the 
degree of red cell iron incorporation.  An additional blood sample will be taken 4 weeks post-
treatment to measure potential differences in the rate of erythropoiesis or red cell destruction 
between infection groups in children treated with placebo (i.e. newly infected vs. uninfected, n=10 
per group) or between treatment groups in newly infected children (n=10 per group). 
 At the 2-week pre-treatment visit, each infant will be given an oral dose of NaBr (1.5 g/kg) 
and 57Fe (7 mg, as ferrous sulfate).  Infants will then be allowed to nurse and will be fed a standard 
meal 1 hour post-dosing.  The majority of prior studies in infants have estimated red blood cell iron 
incorporation at 90% in infants.  This assumption simplifies the studies and allows them to done 
using only a single oral iron isotope57;58.  However, the degree of iron incorporation into red cells 
may be altered in these infants due to subclinical infections.  We will therefore directly measure the 
degree of iron incorporation into red cells by administering a second intravenous iron isotope.  An 
intravenous dose of 58Fe (0.6 mg as ferrous citrate) will be administered over 5 minutes.  Blood 
volume assumptions are also necessary.  Most studies estimate blood volume at 65-80 mL/kg. 
Information obtained from the deuterium (body composition study, see below) and NaBr tracer 
dosing will allow us to directly measure extracellular fluid volume and total body water and 
reduces the assumptions necessary for making calculations about iron metabolism.  A venous blood 
sample will be taken 4 hours after the oral dosing to measure NaBr concentration. 
 At the treatment visit, a 5 mL blood sample will be drawn by venipuncture.  One mL whole 
blood will be digested using ultrapure acids.  Iron will be extracted using cation-exchange 
chromatography.  The eluent will be dried and the iron residue will be dissolved in nitric acid.  Iron 
isotope ratios will be determined using magnetic sector thermal ionization mass spectrometry 
(Finnigan MAT 261, Bremen, FRG).  These methods have been previously described in detail.57-59 
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 Few data have addressed the impact of parasitic infections on the lifespan of erythrocytes in 
infants and the timing of maximal iron incorporation into red cells.  Studies have indicated that the 
lifespan of the erythrocyte is markedly lower in infants than adults60 and a recent study has found 
alterations in the time course of iron incorporation into erythrocytes in infants61.  An additional 
blood sample is already planned at the 1 month post-treatment visit for immunology and protein 
turnover studies.  We will also analyze the enrichment of iron isotopes in these blood samples to 
compare the stability of the tracer enrichments between infection and treatment groups. 
Protein turnover study.  Protein catabolism will be assessed by measuring oxidation of leucine, an 
indispensable amino acid, labelled with a stable tracer62.  The fraction of leucine flux that is 
oxidized is constant under normal conditions, but increases markedly with protein breakdown.  The 
protocol consists of two sequential oral tracer infusions: (1) Measurement of CO2 production: 
bicarbonate tracer (13CO3NaH  (99% APE, Cambridge Isotopes, MA) will be administered as a 
priming oral dose of 0.4 mg/kg, followed by a 3-hour constant oral infusion of 0.4 mg/kg/hr, 
administered in three equal aliquots every 20 minutes62;63.  (2) Measurement of leucine oxidation: 
upon completion of the bicarbonate infusion, the leucine tracer infusion will start. L-[1-13C]-
Leucine (95% APE, Cambridge Isotopes, MA) will be administered as a priming dose of 2 mg/kg, 
followed by a 4-hour constant oral infusion of 2 mg/kg/hr for 4 hours. Doses will be given in 20-
minute aliquots64;65. During the infusion study children will be fed at hourly intervals.  Intake of 
breast milk will be determined by test weighing.  Feeding will approximate the pro-rated calculated 
24-hour energy requirement for actual weight.  Breath air (15 mL) will be sampled for isotopic 
enrichment by asking the child to blow into a small balloon.  
Body composition study.  Body composition will be determined by isotopic dilution, using 
deuterium oxide66. A fixed, 20 g oral dose of  2H2O (99.5APE, Cambridge Isotopes, MA) will be 
administered at the pre-treatment visit at the same time the NaBr is given. Saliva samples will be 
collected at 3 and 3.5 hours post-dose, for measurement of isotopic enrichments.   
 
Data Analysis 
 Data will be entered using an Oracle-based data management system.  Data analysis will be 
directed by Dr. Tielsch, with full participation of the research team to interpret and publish 
findings.  Primary analyses will compare relative risks (Aim 1) or means (Aims 2-5) between 
groups defined by pre-treatment infection status or treatment group, according to the specific aims.   
 
Collaboration 
 The collaboration between The Johns Hopkins University and the Ministry of Health of 
Zanzibar has been ongoing since 1994.  The focus has been epidemiologic research on the relations 
between parasitic infections, anemia and malnutrition. The London School of Hygiene and Tropical 
Medicine (LSHTM, Dr. Bickle, Prof Taylor) is currently collaborating with the PHL to investigate 
whether Zanzibari school children are acquiring resistance to mebendazole after more than a decade 
of mass treatment with that drug.  They are also collaborating with Nanjing Medical University to 
study cytokine and antibody responses and resistance to infection with Schistosoma japonicum in 
humans. This proposal unites the nutrition and epidemiology expertise of JHU with infectious 
disease immunology expertise of the Immunology Unit at LSHTM and the applied health research 
experience and needs of the Pemba PHL.  Each contribution is essential.  In June 2000, Ministry of 
Health of Zanzibar opened the Pemba PHL to serve as a semi-autonomous research body of the 
MOH.  The proposal is designed to equip the PHL with training and technology related to 
epidemiology, parasitology, and metabolism. 
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Training And Technology Transfer 
Three forms of training are integrated into the research plan.  The first is MSc training at an African 
Institution for one Zanzibari scientist, for whom parts of this research will comprise his/her thesis 
research. Second, 2 senior local scientists (Dr. Chwaya, Dr. Mohammed, and the MSc trainee) will 
participate in the 3-week Summer Epidemiology Course offered by JHU in project years 1, 2, and 
3.  This will allow each one to take a total of 6 short intensive courses (2 per year) in epidemiology 
and biostatistics.  Third, 2-person teams from the Immunology and Parasitology Departments of the 
PHL will receive practical training on assessment techniques both at the PHL and in LSHTM 
laboratories.  The foci of the training will be the whole blood assay under the direction of Drs. 
Bickle and Weir, and measurement of acute phase proteins under the direction of Dr. Raynes.  
Practical training in each of these areas will include two parts:  First, a 3-week trip to the US or UK 
laboratory to learn the method, followed by a visit of the UK or US scientist to the PHL to 
supervise the establishment of the method in the PHL.  In addition to training of personnel, this 
proposal will provide the Pemba PHL with key laboratory equipment that will serve not only this 
research plan, but a wide variety of research endeavors in years to come.  This equipment is 
detailed on page 27.  The research plan is designed so that all laboratory work will be conducted at 
the Pemba PHL, with the exception of the analysis of stable isotopes by mass spectrometry which 
requires very specialized and expensive instruments.   
 
Study Limitations 
Young Pemban children are exposed to holo-endemic malaria transmission, a “nuisance” factor that 
may influence the immunological and metabolic studies.  We will assess malaria parasite density at 
each blood draw and consider it as a covariate in our analyses.  Schistosoma haematobium is also 
endemic in Pemba; however we expect these young children will have very limited exposure.  Our 
strongest tool is the randomized intervention design.  If we observe differences between treatment 
groups we can make causal inference about the specific role of helminth infections.  Our 
preliminary data suggest that effects of anthelminthic treatment can be detected and may be large, 
even in the presence of other concurrent parasitic infections. 
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